Beth Fand Incollingo

Androgen-deprivation therapy (ADT) is a mainstay of treatment for prostate cancer in a number of settings, so managing its side effects is becoming increasingly important for urologists in collaboration with oncologists and primary-care physicians.

When Franco Muggia, MD, was a freshly minted oncologist 50 years ago, his new colleagues warned him not to waste much time learning about a drug like fluorouracil.

Ten years ago, Nicholas J. Vogelzang, MD, helped design a study of docetaxel added to first-line androgen deprivation therapy (ADT) in men with newly diagnosed metastatic, hormone-sensitive prostate cancer.

Improved imaging modalities are needed to help advance treatment of men diagnosed with metastatic prostate cancer, and several novel techniques are under study

The immunotherapy drug ipilimumab reduced the relative risk of cancer recurrence in the adjuvant setting by 25% compared to placebo for patients with high-risk, lymph-node positive melanoma.

In what was described as "an almost unprecedented improvement in median survival," the addition of the chemotherapy drug docetaxel to standard hormone therapy prolonged life for men with newly diagnosed metastatic, hormone-sensitive prostate cancer by nearly 14 months.

Lenvatinib, a novel multityrosine kinase inhibitor, is highly effective against differentiated thyroid cancer that has become resistant to standard RAI therapy.

Adding goserelin to chemotherapy for women with early-stage hormone receptor (HR)-negative breast cancer helps both to preserve their fertility and to prolong their survival.

Men given the GnRH antagonist degarelix because their PSA level rose after primary therapy fared at least as well on an intermittent medication schedule as on a continuous schedule

When it comes to detecting prostate cancer accurately and noninvasively, dogs may be ahead by a nose.

In the age of social media, simply having a website isn't enough. To keep existing patients and attract new ones, large urology group practices need to build websites that are connected to social media outlets at every turn, said Peter M. Knapp, Jr, MD.

A rising prostate-specific antigen after surgery or radiation therapy for prostate cancer is not enough reason, on its own, to initiate androgen-deprivation therapy.

A recent study that followed men newly diagnosed with localized prostate cancer for a median 18 years found that immediate radical prostatectomy significantly cut death rates as compared with watchful waiting with treatment upon progression, especially in men with intermediate-risk disease.

Two recent studies have raised questions about current trends in prostate cancer (PC) treatment, one supporting the employment of a little-used strategy-direct treatment of the primary tumor in men who have metastatic PC at diagnosis

A trial (NCT01582672) that will pair a targeted treatment with a vaccine therapy for firstline treatment of renal cell carcinoma (RCC) is recruiting at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute.

Despite being quite popular, the dietary supplements vitamin E and selenium do not protect men from developing prostate cancer, and in fact greatly increase risk in certain patients if taken at doses higher than those recommended

The value of surgery in some women with metastatic breast cancer was challenged by data from studies presented at the recent San Antonio Breast Cancer Symposium

Obesity increases the chance that someone will get the clear-cell form of renal cell carcinoma (ccRCC). But once an obese patient has the disease, he's likely to survive longer than a non-obese patient.

During the annual meeting of the Large Urology Group Practice Association (LUGPA) in Chicago in November 2013, the organization's president, Deepak A. Kapoor, MD, completed his 2-year term and handed the gavel to incoming president Juan A. Reyna, MD.

A recently approved indication for nab-paclitaxel (Abraxane) in metastatic pancreatic cancer is thought to have similar efficacy to a standard first-line treatment for the disease, but offers several advantages in the eyes of community oncologists and their patients

Breast cancer survivors who took two yoga classes a week for 3 months after treatment were less fatigued and demonstrated less systemic inflammation than their counterparts who did not take the classes

Men with clinically localized prostate cancer who were treated with radiotherapy were more likely, over the subsequent 5 years, to be admitted to a hospital, undergo rectal, anal, or open surgical procedures, or develop secondary malignancies than men treated with radical prostatectomy

Screening for prostate-specific antigen (PSA) significantly cuts the death rate from prostate cancer, so America's medical community should continue to offer the test to appropriate men, but at the same time should work harder to avoid the screen's potential pitfalls.

Insights about PSA screening, genomics, and what's new in the areas of imaging, antiandrogen therapy, radiation therapy, immunotherapy, and radiopharmaceuticals will be offered during the 7th Annual IPCC.

Brisk walking helps normalize the shape of vessels in prostate cancer tumors, which may make the tumors less aggressive and more responsive to anti-cancer therapies

The large Canadian study that has caused a stir by indicating that mammograms are of no use in women aged 40 to 59 years, and in fact can lead to over-diagnosis of breast cancer, is flawed and misleading

An immunotherapy drug for the treatment of prostate cancer, approved in the US in 2010, will soon be available in Europe.

Some patients with micropapillary urothelial carcinoma face a three-fold risk of cancer death because their disease amplifies HER2 and overexpresses its protein product, and there may be a role for treatment of the condition with HER2- targeted agent trastuzumab, which has vastly increased the odds of survival for eligible patients with breast cancer.

Long-term outcomes for patients with prostate cancer following radical prostatectomy were better when a spinal or epidural pain block was added to general anesthesia during the surgery.

A crop of targeted agents have demonstrated promising results in fighting chronic lymphocytic leukemia (CLL), suggesting that a range of emerging therapies and drug combinations may be more effective and better tolerated than standard chemotherapy